LIDDS tillkännager framgångsrikt slutförande av steg 1 i forskningssamarbete
11 janv. 2022 11h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) tillkännagav i dag att forskningssamarbetet med Johnson & Johnson Enterprise Innovation Inc har fortsatt in i nästa fas. ”Genom ett starkt samarbete har...
LIDDS announces successful stage 1 in R&D project
11 janv. 2022 11h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the R&D project with Johnson & Johnson Enterprise Innovation Inc. has progressed into next phase. “On the back of a strong...
LIDDS tillkännager positiva topline resultat från den dos-eskalerande fas I studien av NanoZolid®-formulerad docetaxel
29 déc. 2021 04h00 HE
|
LIDDS AB
UPPSALA, SVERIGE – LIDDS AB (publ) tillkännagav i dag att den systemiska exponeringen av docetaxel efter behandling av solida tumörer med NanoZolid®-formulerad docetaxel är låg och att studien visar...
LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
29 déc. 2021 04h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both...
LIDDS utser Matthew Lindon till Chief Scientific Officer
20 déc. 2021 09h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) tillkännagav i dag att Matthew Lindon har utsetts till Chief Scientific Officer (CSO) för LIDDS AB. Matthew Lindon har över 20 års erfarenhet av drug discovery och...
LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
20 déc. 2021 09h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Matthew Lindon has been appointed Chief Scientific Officer (CSO) of LIDDS AB. Matthew Lindon has over 20 years experience of drug discovery and...
LIDDS patent covering the NanoZolid® production process granted in China
17 déc. 2021 03h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in China. The...
LIDDS Interim report January – September 2021
22 nov. 2021 10h45 HE
|
LIDDS AB
JANUARY – SEPTEMBER 2021 Net sales amounted to MSEK 1.2 (0.0)Operating expenses amounted to MSEK -29,5 (-19,8)Profit/loss before and after tax amounted to MSEK -28.4 (-19.8)Earnings per share...
Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
17 nov. 2021 04h00 HE
|
LIDDS AB
November 17, 2021 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS UPPSALA, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for...
LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
15 nov. 2021 05h00 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Johan Harmenberg has been appointed Chief Medical Officer (CMO) of LIDDS AB. Johan Harmenberg has extensive experience from the pharmaceutical...